Six-month Outcome of Immunocompromised Severe ARDS Patients Rescued by ECMO. An International Multicenter Retrospective Study by M. Schmidt et al.
Six-month Outcome of Immunocompromised Severe ARDS
Patients Rescued by ECMO. An International Multicenter
Retrospective Study
Submitted by Beatrice Guillaumat on Wed, 08/28/2019 - 11:36
Titre Six-month Outcome of Immunocompromised Severe ARDS Patients Rescued byECMO. An International Multicenter Retrospective Study
Type de
publication Article de revue
Auteur
Schmidt, Matthieu [1], Schellongowski, Peter [2], Patroniti, Nicolò [3], Taccone,
Fabio Silvio [4], Reis Miranda, Dinis [5], Reuter, Jean [6], Prodanovic, Helène [7],
Pierrot, Marc [8], Dorget, Amandine [9], Park, Sunghoon [10], Balik, Martin [11],
Demoule, Alexandre [12], Crippa, Ilaria Alice [13], Mercat, Alain [14], Wohlfarth,
Philipp [15], Sonneville, Romain [16], Combes, Alain [17]
Organisme International ECMO Network (ECMONet) [18], REVA Research Networ [19], IDEAStudy Group [20]
Editeur ATS Journal
Type Article scientifique dans une revue à comité de lecture
Année 2018
Langue Anglais





revue American Journal of Respiratory and Critical Care Medicine
ISSN 1535-4970
Mots-clés Acute respiratory distress syndrome [21], Extracorporeal Membrane Oxygenation[22], hematological malignancies [23], immunodeficiency [24], outcome [25]
Résumé en
anglais
OBJECTIVES: To report outcomes of immunocompromised patients treated with
extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress
syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and
main ECMO-related complications.
METHODS: Retrospective multicenter study in 10 international intensive care units
(ICUs) with high ECMO-case volumes. Immunocompromised patients, defined as
having hematological malignancies, active solid tumor, solid-organ transplant,
acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or
immunosuppressant use, and severe ECMO-treated ARDS from 2008 to 2015 were
included Measurements and Main Results: We collected demographics, clinical,
ECMO-related complications, ICU- and 6-month-outcome data for 203 patients
(median APACHE II 28 [25th ;75th percentile, 20;33]; age 51 [38;59] years,
PaO2/FiO2 60 [50;82] mmHg before ECMO) who fulfilled our inclusion criteria. Six-
month survival was only 30%, with a respective median ECMO duration and ICU stay
of 8 [5;14] and 25 [16;50] days. Patients with hematological malignancies had
significantly poorer outcomes than others (log-rank P=0.02). Multivariate analyses
retained <30 days between immunodeficiency diagnosis and ECMO cannulation as
being associated with lower 6-month mortality (odds ratio 0.32 (95% confidence
interval 0.16-0.66); P=0.002), and lower platelet count, higher PCO2, age and driving
pressure as independent pre-ECMO predictors of 6-month mortality.
CONCLUSION: Recently diagnosed immunodeficiency is associated with a much
better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of
our large cohort of immunocompromised patients supports restricting ECMO to
patients with realistic oncological/therapeutic prognoses, acceptable functional
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